Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 770 participants.

Also called NCT02304484

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 770 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02304484
  • EudraCT 2014-001524-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02304484. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11-24 (actual); primary completion 2018-03-09 (actual). Results posted on 2019-03-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
Condition
Hypercholesterolemia
Intervention (Biological)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02304484
Content hash
e00cfd5770f3cf42721c1af38be3f7f985fb03371d6402d337e7c51194dbf791